News 28.05.2026 Zürich, Switzerland, May 28, 2026 – Topadur Pharma AG, a Swiss clinical-stage biopharmaceutical company, today announced that Dr. Felix R. Ehrat and Dr. Peter Jager have been elected to its Board of Directors at the company's Annual General Meeting. Both join the Board with immediate effect. The appointments add deep strategic and...
News 27.05.2026 Schlieren (Zurich), May 26, 2026 –LimmaTech Biologics AG, a Swiss clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, today announced entry into a definitive agreement to be acquired by Lilly. LimmaTech is developing vaccines against bacterial pathogens for which rising antimicrobial resistance is steadily closing therapeutic options, including...
News 20.05.2026 Schlieren, Switzerland - May 20, 2026 Strategic acquisition strengthens InSphero’s presence in the United States and expands advanced imaging and phenotypic analysis capabilities for drug discovery and safety testing InSphero, the global leader in advanced 3D in vitromodels and services for drug safety and efficacy testing, today announced the acquisition of California-based...
News 19.05.2026 Schlieren/Zurich, Switzerland, May 19, 2026 - Mabylon AG, a leader in the discovery and development of human-derived, half-life extended multi-specific antibodies, today reported preliminary positive Phase Ia data demonstrating a favorable safety profile of its lead candidate MY006 in an ongoing first-in-human trial. Mabylon also announced the initiation of dosing...
News 15.05.2026 CUTISS has been granted a new U.S. patent. It covers automated methods and systems for producing skin grafts, including the separation of skin layers and the isolation of key cell types from a skin biopsy. The patented invention relates to a broader automated workflow for skin graft production, in which a...